SCHOTT Pharma AG & Co KgaA (1SXP)

Currency in EUR
15.30
-0.12(-0.78%)
Closed·

1SXP Earnings

Latest Release
Feb 08, 2026
EPS / Forecast
0.22 / 0.17
Revenue / Forecast
240.19M / 223.13M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
2026/03--/0.211--/245.73M----Free Sign Up
2025/120.220/0.168240.19M/223.13M+30.95%+7.65%Free Sign Up
2025/090.221/0.235247.61M/248.32M-5.87%-0.29%Free Sign Up
2025/060.300/0.288256.46M/266.52M+4.13%-3.77%Free Sign Up
2025/030.260/0.217252.00M/240.25M+19.71%+4.89%Free Sign Up
2024/120.190/0.273230.00M/255.22M-30.38%-9.88%Free Sign Up
2024/090.228/0.163237.00M/259.71M+40.01%-8.74%Free Sign Up
2024/060.304/0.270253.74M/244.83M+12.44%+3.64%Free Sign Up
2024/030.166/0.170234.05M/234.05M-2.24%0%Free Sign Up
2023/120.292/0.290232.30M/232.20M+0.83%+0.04%Free Sign Up

All numbers in EUR

SCHOTT Pharma AG & Co KgaA Earnings Call Summary for Q1/2026

  • SCHOTT Pharma reported Q1 FY2026 revenue of €240M (+4.8% YoY), with EPS of €0.22 exceeding forecasts of €0.168, driving stock up 6.12% to €15.60
  • Drug Containment Solutions segment grew 9.4% at constant currencies, while Drug Delivery Systems remained flat; EBITDA increased 11% YoY to €65M with 27.1% margin
  • Company maintained FY2026 guidance of 2-5% revenue growth and ~27% EBITDA margin, with planned capital expenditures of €140-160M for high-value solutions
  • CEO Andreas Reisse emphasized high-value solutions as essential for profitable growth, targeting to increase their revenue share to exceed 60% mid-term
  • Potential risks include supply chain disruptions, market saturation, currency fluctuations, regulatory changes, and intense competition in pharmaceutical packaging
Last Updated: 2026-02-11, 05:50 a/m
Read Full Transcript

FAQ

What Is SCHOTT Pharma's Earnings Per Share (TTM)?

The SCHOTT Pharma EPS (TTM) is 0.99.

When Is The Next SCHOTT Pharma Earnings Date?

SCHOTT Pharma will release its next earnings report on May 13, 2026.

What Is SCHOTT Pharma’s Revenue Forecasts For Upcoming Quarters?

SCHOTT Pharma’s revenue forecast is 245.73M.

How Did SCHOTT Pharma React to the Company's Latest Earnings Report?

SCHOTT Pharma reported a +30.95% EPS surprise and a +7.65% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by -0.28%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.